Peptide-PNA conjugates: Targeted transport of antisense therapeutics into tumors

Angewandte Chemie - International Edition

Volumn 42, Issue 17, 2003, Pages 1968-1971

  Mier, Walter ^a   Eritja, Ramon ^b   Mohammed, Ashour ^a   Haberkorn, Uwe ^a   Eisenhut, Michael ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CSIC   (Spain)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antisense agents; Drug delivery; Peptide nucleic acids; Peptides; Solid phase synthesis

Indexed keywords

NUCLEIC ACIDS; TUMORS;

ANTISENSE THERAPEUTICS;

ORGANIC POLYMERS;

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; HUMAN; HYBRID; IN VITRO STUDY; MALE; NONHUMAN; PROTECTION; RAT; SYSTEMIC DISEASE;

ANIMALS; CEREBRAL CORTEX; GENE THERAPY; INDICATORS AND REAGENTS; MEMBRANES; NEOPLASMS; PEPTIDE NUCLEIC ACIDS; PEPTIDES; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TISSUE DISTRIBUTION;

EID: 0037877997     PISSN: 14337851     EISSN: None     Source Type: Journal    
DOI: 10.1002/anie.200219978     Document Type: Article

References (19)

1. a) R. G. Cooper, R. P. Harbottle, H. Schneider, C. Coutelle, A. D. Miller, Angew. Chem. 1999, 111, 2128-2132
2. a) R. G. Cooper, R. P. Harbottle, H. Schneider, C. Coutelle, A. D. Miller, Angew. Chem. 1999, 111, 2128-2132
3. b) J. D. Hood, M. Bednarski, R. Frausto, S. Guccione, R. A. Reisfeld, R. Xiang, D. A. Cheresh, Science 2002, 296, 2404-2407.
4. W. Bauer, U. Briner, W. Doepfner, R. Haller, R. Huguenin, P. Marbach, T. J. Petcher, J. Pless, Life Sci. 1982, 31, 1133-1140.
5. C. M. Huang, Y. T. Wu, S. T. Chen, Chem. Biol. 2000, 7, 453-461.
6. The expression of the proto-oncogene bcl-2 increases the susceptibility of tumor cells towards undergoing apoptosis. The anti-bcl-2 phosphorothioate oligonucleotide G3139 (Genasense) belongs to the antisense oligonucleotides, whose clinical development is most advanced.
7. L. Mologni, P. E. Nielsen, C. Gambacorti-Passerini, Biochem. Biophys. Res. Commun. 1999, 264, 537-543.
8. W. Mier, R. Eritja, A. Mohammed, U. Haberkorn, M. Eisenhut, Bioconjugate Chem. 2000, 11, 855-860.
9. 32P-labeled conjugate revealed a preferential accumulation in the liver, kidneys, and the spleen, similarly to a phosphorothioate without the peptide moiety.
10. a) P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science 1991, 254, 1497-1500;
11. b) E. Uhlmann, A. Peyman, G. Breipohl, D. W. Will, Angew. Chem. 1998, 110, 2954-2983; Angew. Chem. Int. Ed. 1998, 37, 2796-2823.
12. b) E. Uhlmann, A. Peyman, G. Breipohl, D. W. Will, Angew. Chem. 1998, 110, 2954-2983; Angew. Chem. Int. Ed. 1998, 37, 2796-2823.
13. S. K. Awasthi, P. E. Nielsen, Comb. Chem. High Throughput Screening 2002, 5, 253-259.
14. L. P. Miranda, P. F. Alewood, Proc. Natl. Acad. Sci. USA 1999, 96, 1181-1186.
15. a) L. Christensen, R. Fitzpatrick, B. Gildea, K. H. Petersen, H. F. Hansen, T. Koch, M. Egholm, O. Buchardt, P. E. Nielsen, J. Coull, R. H. Berg, J. Pept. Sci. 1995, 1, 175-183;
16. b) T. Koch, H. F. Hansen, P. Andersen, T. Larsen, H. G. Batz, K. Otteson, H. Orum, J. Pept. Res. 1997, 49, 80-88.
17. F. C. Greenwood, W. M. Hunter, J. S. Glover, Biochem. J. 1963, 89, 114-123.
18. a) L. C. Boffa, S. Scarfi, M. R. Mariani, G. Damonte, V. G. Allfrey, U. Benatti, P. L. Morris, Cancer Res. 2000, 60, 2258-2262;
19. b) L. J. Branden, A. J. Mohamed, C. I. Smith, Nat. Biotechnol. 1999, 17, 784-787.